No abstract

. (2016). Phase IIb clinical trial of ranibizumab for the treatment of uveitic and idiopathic choroidal neovascular membranes. British Journal of Ophthalmology, 100(9), 1221 -1226 . DOI: 10.1136 /bjophthalmol-2015 Peer reviewed version Link to published version (if available): 10.1136/bjophthalmol-2015-307806 Link to publication record in Explore Bristol Research PDF-document This is the author accepted manuscript (AAM). The final published version (version of record) is available online via BMJ at http://bjo.bmj.com/content/100/9/1221. Please refer to any applicable terms of use of the publisher. University of Bristol -Explore Bristol Research General rightsThis document is made available in accordance with publisher policies. Please cite only the published version using the reference above. There was a statistically significant difference in the BCVA at month 4 (p=0.001) and at month 12 (p=0.001) compared with baseline. The mean gain in BCVA at month 4 compared with baseline was 20±15.36 letters (mean ± SD), and at month 12 was 21±16.97 letters. There was a statistically significant difference in the mean central subfield thickness (CST) at baseline versus month 4 (p=0.003) and month 12 (p=0.001). Conclusions:Patients gained vision (mean of 21 letters at 12 months) and showed reduced CST. These results support the continued use of Ranibizumab in the treatment of iCNV.

No abstract

No abstract